On January 22nd, the New England Journal of Medicine published the results of an international phase II clinical trial co-authored by Dr. Peter Martin. The trial was designed to evaluate the efficacy of the oral drug idelalisib in patients with indolent non-Hodgkin lymphoma resistant to chemotherapy and rituximab. The results were remarkable in this challenging-to-treat population. Highlights from the publication include the following:
- Idelalisib was well tolerated.
- The majority of patients responded and the average time to response was 1.9 months.
- Continued use of idelalisib saw sustained responses beyond 1 year, exceeding responses of prior therapy.
